TET2 and glioblastoma: These results show, for the first time, that loss of TET2 directly affects the stem cell and tumor phenotype of GBM cells and predict that strategies focused on re-expressing TETs and/or normalizing 5hmC levels can be developed as anti-cancer molecular therapeutics.